Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PURE BiosciencePURE Debt-to-Equity is -1.11 as of Apr. 2026. The stock has 5 warning signs investors should review. Among 1,747 Consumer Packaged Goods companies, PURE Bioscience ranks worse than 57240.93% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PURE Bioscience's Debt-to-Equity or its related term are showing as below:
PURE'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4.77 Med: -1.01 Max: 3.75
Current: -1.11
During the past 13 years, the highest Debt-to-Equity Ratio of PURE Bioscience was 3.75. The lowest was -4.77. And the median was -1.01.
PURE's Debt-to-Equity is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 0.41
vs PURE: -1.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PURE Bioscience Debt-to-Equity Related Terms
PURE Bioscience Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PURE Bioscience's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE vs DQWS, TANH, DSY: Debt-to-Equity Comparison
For the Household & Personal Products subindustry, PURE Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PURE Bioscience Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PURE Bioscience's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience (PURE) has a Debt-to-Equity of -1.11 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PURE Bioscience and its competitors. According to the industry distribution chart, PURE Bioscience ranks #999999 out of 1747 companies in the Consumer Packaged Goods industry.
Is PURE Bioscience's Debt-to-Equity too high?
PURE Bioscience's current Debt-to-Equity is -1.11. Based on the distribution chart, PURE Bioscience ranks #999999 out of 1747 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers.
How does PURE Bioscience's Debt-to-Equity compare to DQWS and TANH?
According to the Consumer Packaged Goods industry distribution chart, PURE Bioscience ranks #999999 out of 1747 companies for Debt-to-Equity. This places PURE Bioscience in the lower half of its industry. The industry median Debt-to-Equity is 0.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,747 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PURE Bioscience and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PURE Bioscience's current Debt-to-Equity is -1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.10, compared to a current price of $0.08 — trading 20% below its estimated fair value. The current Debt-to-Equity is -1.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PURE Bioscience (PURE), the current Debt-to-Equity is -1.11 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PURE has been successfully added to your 
